MEMORANDUM FOR BOARD MEETING OF 29 JUNE 2005,
PHARMAC Directors,
Sean Dougherty
21 tune 2005
OXYCODONE HYDROCHLORIDE,
Recommendations
es recommended that having regard to the decision eriteri set out in Section 2.2 of PHARMAC’S
(Operating Policies end Procedres yo
resolve fo list oxycodone fyochloride in the Opioid Analgesics therapevic subgroup of
‘Seaton B and in art I'ofSeetionH of the Phamaceutial Schedule fom | August 2008s
fellows:
Presentation Brand ‘Seengih Pack Sie PrcalSubaiy
Capsies Onto Sa Ey 323
Caos one toma = 3588
Cepaes one 2009 = er
Cconmolcraease tats OryCantn 10m = sre
CConcocreease itis OyComtn 20m = srass
Coneolcreess tats OnConin 400 2 sxa20
Contolcreeaselatets___OnCantn 079 ES sea03
revolve to apply the folowing rernction to the presenbing of oxyvodane capsules end
‘conzlledeessed eles in Seton B of the Pharaceutesl Schedule
Only ona controled de frm,
resolve to apply the following guideline to the presribing of oxycodone capsules and
contllod ceased tablets in Secon Bf he Pharmaceutical Sshedue:
Prescribing Gatdeline
Presrbers should note hat oxycodone is significantly more expensive thn ong acting
‘morphine sulphate and clinical vie suggests tai s reasonable to consider tis asa
Seeondiine agent oe used afer morphine
note tat the agreement provides for the isting ofthe flowing presentation stuld regulatory
pprovl and other consents be granted:
‘Seongth Peck Sze PrcelBubeay
‘Oxycone 5 a S751
resolve to approve the 17 May 2005 agreement with Mundipharma New Zealand Limited in ts
entity
5.1.20 91139 1Supplier
[MOH Restretons
‘OxyNom, OxyConin—_—_Chemleal Name
Presentation
Opioid amigesis Nervous Pharmaceutical Type
Sen)
Manila New Zea Applcaton Date
Time
Cones Drag (53)
‘Oneedane
yocterise
‘soled eleaee
ew cere entity
‘Aes 2004
‘Careat eb NI
Proposed subsidy Caples
5285 per20
sss8per20
$9.7 per20
Controle abet
$781 per20
siti per20
1893 per20
33329 pec20
$5803 per 20
Proposed restriction Olona contol dg fom.
or Na Secon F %
Market ata VERO Tawa E30 Te 2007 YEW Tne 2008
Subsidy Grom) se4o00 1,200,000 1,800,000
Net eos to Schedule san 00 93000 200,000
Net cost to Dt 2000 830,000 200,000
Net os to DUBS (NPV) $s,000,000
10 Ss (rom) ~ forecast of spnting on oxycodone tthe propose subs
2. Natecu to Sele = foes of thang tol spending on pharmacticalsted onthe Sched
empath ts goo
‘Nitou o Dis = Net cost te Seed
Alco are expese ex mauler, eacoing OS
[NPV isclaltod ove $year using am noma dssun rate of 10%
Catto in Doe 057725
5.4.20 #91139Executive Summary
‘Key Issues inthe Proposal
+ Listing oxycodone, a strong opioid analgesic, inthe Pharmaceutical Schedule would provide an
tlernative teatment option to morphine sulphate tablets and eapsues. It has simi efficcy and
tolerability, but will allow for opoid rotation and further weatment options whea marine Is aot
tolemte,
+ fy 2002, the review of analgesic agent by tbe newly formed Analgesic and Antiemetic
SuBcommtee of PTAC (now the Analgesic Somme of PTAC) highlights several gaps in
‘he publicly iunded lst of analgesic agents; the Subcammitee recommended that PHARMAC Ist,
nother song opioid analgesic as an alternative to morphine.
‘+ ‘The Analgesic Review Board paper in April 2005 highlighted fare tke gaps in analgesia
treatment available in New Zealand, and noted that PHARMAC staff were pursuing the listing of
‘erycodane a a aerate stongopiid analgesic
‘+The listing of oxycodone in Sein B of the Pharmaceutical Schedule would be ssoiated with 3
small cost increase inthe fist ew year, withthe estited increase in expend in the fh
‘ar being les han $2,000,009.
‘Why Proposl not desided under Delegated Authority
‘The proposal outlined inthis Board paper tus not been dealt with by the CEO ander detested
suthry beste the Board has requested o be fvolved in ll erent investment deshions
‘The proposal
+ Listing oxyeodane hytochlorde capsules and controlled lease tbls in Section 8 ain Pat TL
‘of Secon Hof he Pharmaceutical Sehodule
+ Listing further presentation ofthe contol release tablet later ime following registro,
[Note an agreement, consional on consulation and Board approval, between Midian New
Zealand Limited and PHARMAC dated 17 May 2005 is atached ss Appendix 1
timate oft
fects of the proposal
Given the experience of oxycodone in Ansell, PHARMAC staff ancpate thatthe market for
‘oxyeodone wil prow gradually, increasing make sare ove long-acting morphine by around 5% per
yea. Overall marketshare i anticipated abe:
nam Ee a 0 es AO
6 15% 20% 25%, 30%
Shortactng asycodone
The Hinting of the shortacting formulation i anticipated to have 4 minimal efeet on the
pharmaceutical budget. Is pricing is substantially lower per tblet than th equivalent dose of shor-
‘Soting formulations of morphine sulphate, vie
5.4.20 491139 3